Bladder Cancer Coverage from Every Angle

Thomas Powles, MD, PhD, on Clinical Implications of the NORSE Trial: Erdafitinib Plus Cetrelimab in FGFR-Altered Advanced Urothelial Carcinoma

Posted: Wednesday, October 13, 2021

Thomas Powles, MD, PhD, of Queen Mary University of London, discusses practical clinical issues raised by the NORSE study of patients with first-line metastatic or locally advanced urothelial carcinoma and fibroblast growth factor receptor (FGFR) alterations who received the kinase inhibitor erdafitinib plus the monoclonal antibody cetrelimab. A small percentage of patients with this disease are ineligible to receive cisplatin as first-line treatment due to FGFR alterations.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.